Breakthrough in Mitochondrial Gene Therapy: Research Offers Promising New Approach

Scientists at Hokkaido University have made a groundbreaking discovery in the field of gene therapy, developing a novel method for delivering the CRISPR/Cas9 system directly into the mitochondria of cells. The innovative approach, known as RNP-MITO-Porter, utilizes a lipid nanoparticle delivery system to target a point mutation in mitochondrial DNA (mtDNA) that can cause mitochondrial diseases.

Key Takeaways:

  • Researchers at Hokkaido University have successfully delivered the CRISPR/Cas9 system directly into the mitochondria of cells using a lipid nanoparticle delivery system.
  • The RNP-MITO-Porter method targets a point mutation in mitochondrial DNA (mtDNA) that can cause mitochondrial diseases.
  • The study demonstrated the effectiveness of RNP-MITO-Porter in causing sequence-specific double-strand breaks in mtDNA, a crucial step in gene editing.
  • The research has significant implications for the clinical application of mitochondrion-targeted gene therapy, with the potential to treat various mitochondrial diseases.
  • The study was published in Scientific Reports, a leading international journal.

Statistics:

  • 95% of cells treated with RNP-MITO-Porter experienced sequence-specific double-strand breaks in mtDNA (Source: Lipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G T mutation in MtDNA (mt-Atp8))
  • The study demonstrated the effectiveness of RNP-MITO-Porter in delivering the CRISPR/Cas9 system to mitochondria of cells derived from a mouse carrying a point mutation (m.7778G T) in mtDNA (mt-Atp8)
  • The research was conducted using HeLa cells, a commonly used cell line in scientific research

Sources:

  • Lipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G T mutation in MtDNA (mt-Atp8). Scientific Reports, 2025;15(1):18717.
  • NewsRx. Hokkaido University Reports Findings in Gene Therapy [Lipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G T mutation in MtDNA (mt-Atp8)]. Nanotechnology Weekly. June 30, 2025; p 416.